| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Appendiceal Neoplasms | 6 | 2024 | 251 | 1.000 |
Why?
|
| Colitis | 4 | 2022 | 344 | 0.620 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2016 | 68 | 0.530 |
Why?
|
| Simplexvirus | 1 | 2016 | 180 | 0.520 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 98 | 0.500 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2023 | 1825 | 0.430 |
Why?
|
| Nasopharyngeal Neoplasms | 14 | 2003 | 338 | 0.420 |
Why?
|
| Bone Marrow Transplantation | 1 | 2016 | 1772 | 0.360 |
Why?
|
| Colorectal Neoplasms | 5 | 2023 | 3705 | 0.330 |
Why?
|
| Antiviral Agents | 1 | 2016 | 1255 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 6 | 2023 | 5248 | 0.320 |
Why?
|
| Adenocarcinoma | 6 | 2024 | 7981 | 0.300 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 1014 | 0.290 |
Why?
|
| Biopsy | 6 | 2020 | 3543 | 0.250 |
Why?
|
| Observer Variation | 2 | 2024 | 720 | 0.240 |
Why?
|
| Bile Duct Neoplasms | 2 | 2021 | 498 | 0.240 |
Why?
|
| Cholangiocarcinoma | 2 | 2021 | 501 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 5214 | 0.220 |
Why?
|
| Immunohistochemistry | 6 | 2024 | 7832 | 0.220 |
Why?
|
| Anus Neoplasms | 2 | 2017 | 417 | 0.210 |
Why?
|
| Peritoneal Neoplasms | 2 | 2023 | 858 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 3148 | 0.210 |
Why?
|
| Pancreatitis, Chronic | 1 | 2023 | 128 | 0.210 |
Why?
|
| DNA Mismatch Repair | 2 | 2023 | 284 | 0.210 |
Why?
|
| Middle Aged | 38 | 2024 | 90447 | 0.200 |
Why?
|
| Interleukin-6 | 2 | 2022 | 1060 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2017 | 5606 | 0.190 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Diarrhea | 2 | 2021 | 730 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2023 | 443 | 0.170 |
Why?
|
| Ipilimumab | 1 | 2024 | 759 | 0.170 |
Why?
|
| Eosinophilia | 1 | 2021 | 188 | 0.160 |
Why?
|
| Intestinal Perforation | 1 | 2020 | 108 | 0.160 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 180 | 0.160 |
Why?
|
| Neoplasms | 6 | 2024 | 15913 | 0.160 |
Why?
|
| Aged | 31 | 2024 | 73494 | 0.160 |
Why?
|
| Hyperthermia, Induced | 1 | 2023 | 511 | 0.160 |
Why?
|
| Biomarkers, Tumor | 5 | 2024 | 10756 | 0.160 |
Why?
|
| Genomics | 3 | 2021 | 2824 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 5418 | 0.160 |
Why?
|
| Male | 38 | 2024 | 129048 | 0.160 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 367 | 0.150 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 562 | 0.150 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 107 | 0.140 |
Why?
|
| Aged, 80 and over | 21 | 2024 | 31062 | 0.140 |
Why?
|
| Patient Comfort | 1 | 2016 | 7 | 0.140 |
Why?
|
| Foscarnet | 1 | 2016 | 19 | 0.140 |
Why?
|
| Humans | 49 | 2024 | 271967 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 1658 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2021 | 1435 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2018 | 706 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2016 | 490 | 0.140 |
Why?
|
| Acyclovir | 1 | 2016 | 80 | 0.140 |
Why?
|
| Stem Cell Factor | 1 | 2016 | 88 | 0.130 |
Why?
|
| Transaminases | 1 | 2016 | 82 | 0.130 |
Why?
|
| Smad2 Protein | 1 | 2016 | 92 | 0.130 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 70 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 4496 | 0.130 |
Why?
|
| Valine | 1 | 2016 | 180 | 0.130 |
Why?
|
| Female | 37 | 2024 | 149251 | 0.130 |
Why?
|
| Bile Ducts | 1 | 2016 | 115 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 1387 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2020 | 947 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1092 | 0.120 |
Why?
|
| Adult | 28 | 2024 | 81964 | 0.120 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2015 | 41 | 0.120 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 295 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 617 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2017 | 10369 | 0.120 |
Why?
|
| Liver | 4 | 2017 | 3127 | 0.120 |
Why?
|
| Microsatellite Instability | 3 | 2023 | 409 | 0.120 |
Why?
|
| Prognosis | 11 | 2023 | 22542 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2016 | 835 | 0.120 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2014 | 39 | 0.120 |
Why?
|
| Mesothelioma | 1 | 2019 | 560 | 0.120 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2014 | 107 | 0.120 |
Why?
|
| Calcinosis | 1 | 2017 | 431 | 0.110 |
Why?
|
| Tissue Array Analysis | 2 | 2012 | 760 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 2650 | 0.110 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 481 | 0.110 |
Why?
|
| Retrospective Studies | 23 | 2024 | 39817 | 0.110 |
Why?
|
| Cholestasis | 1 | 2016 | 206 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2023 | 1335 | 0.110 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 4819 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 520 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 566 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 1266 | 0.100 |
Why?
|
| Neoplasm Staging | 11 | 2018 | 14003 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 16630 | 0.100 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 520 | 0.100 |
Why?
|
| Lymphangioma, Cystic | 1 | 2012 | 23 | 0.100 |
Why?
|
| Survival Rate | 9 | 2023 | 12545 | 0.100 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2012 | 110 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2014 | 613 | 0.090 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2012 | 227 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2012 | 249 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 3512 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 3036 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1839 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3395 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 2017 | 2123 | 0.080 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2023 | 510 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 1015 | 0.080 |
Why?
|
| Young Adult | 6 | 2021 | 22167 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2012 | 507 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1949 | 0.070 |
Why?
|
| Trans-Activators | 1 | 2014 | 1653 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 7794 | 0.070 |
Why?
|
| Neoplasm Metastasis | 4 | 2024 | 5330 | 0.070 |
Why?
|
| Lymphoma | 1 | 2016 | 1513 | 0.070 |
Why?
|
| Colonoscopy | 2 | 2021 | 522 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 3239 | 0.070 |
Why?
|
| Pancreatectomy | 2 | 2023 | 696 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4989 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5183 | 0.060 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 2804 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4391 | 0.060 |
Why?
|
| Mutation | 4 | 2020 | 15952 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1827 | 0.060 |
Why?
|
| Risk Factors | 5 | 2021 | 18028 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 1442 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2024 | 237 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 2174 | 0.050 |
Why?
|
| CA-19-9 Antigen | 1 | 2024 | 155 | 0.050 |
Why?
|
| Frozen Sections | 1 | 2023 | 118 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1995 | 303 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6275 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2024 | 228 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3018 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 16252 | 0.050 |
Why?
|
| Leucovorin | 1 | 2023 | 345 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 2288 | 0.050 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2021 | 33 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2358 | 0.050 |
Why?
|
| Age Distribution | 2 | 2019 | 730 | 0.050 |
Why?
|
| Mucins | 1 | 2023 | 289 | 0.050 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 78 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2023 | 453 | 0.050 |
Why?
|
| Adolescent | 14 | 2019 | 32743 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2021 | 84 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 155 | 0.050 |
Why?
|
| Treatment Outcome | 8 | 2021 | 33911 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 276 | 0.050 |
Why?
|
| Time Factors | 6 | 2020 | 13129 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 45 | 0.040 |
Why?
|
| Chromogranins | 1 | 2020 | 88 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2021 | 224 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2021 | 150 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2020 | 3671 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2023 | 13398 | 0.040 |
Why?
|
| Radiation Tolerance | 2 | 2020 | 636 | 0.040 |
Why?
|
| Pancreas | 1 | 2023 | 746 | 0.040 |
Why?
|
| Thioguanine | 1 | 2019 | 70 | 0.040 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2021 | 333 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 465 | 0.040 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 10260 | 0.040 |
Why?
|
| Lymphatic Metastasis | 6 | 2017 | 4971 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 351 | 0.040 |
Why?
|
| Analysis of Variance | 5 | 2003 | 2330 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 277 | 0.040 |
Why?
|
| Asparaginase | 1 | 2019 | 198 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2023 | 1989 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2022 | 3545 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2019 | 314 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 701 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 499 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 669 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1438 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 14647 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 1132 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 28 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 372 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 6883 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 6237 | 0.040 |
Why?
|
| Genes, ras | 1 | 2020 | 681 | 0.040 |
Why?
|
| Age Factors | 3 | 2020 | 5516 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2002 | 1379 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 1701 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 9097 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1054 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 164 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 12035 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 15264 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 148 | 0.030 |
Why?
|
| Colon | 1 | 2020 | 691 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2019 | 9476 | 0.030 |
Why?
|
| Gastritis | 1 | 2019 | 405 | 0.030 |
Why?
|
| Carcinoma | 2 | 1999 | 2624 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2019 | 659 | 0.030 |
Why?
|
| Nose Neoplasms | 1 | 1998 | 236 | 0.030 |
Why?
|
| Mice | 3 | 2022 | 36023 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1401 | 0.030 |
Why?
|
| Proportional Hazards Models | 6 | 2003 | 5110 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 532 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 1125 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2357 | 0.030 |
Why?
|
| Radiation Injuries | 2 | 2000 | 1472 | 0.030 |
Why?
|
| Bilirubin | 1 | 2016 | 224 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 272 | 0.030 |
Why?
|
| Gene Components | 1 | 2014 | 16 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2864 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 1565 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 5063 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 14882 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 1904 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 449 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 6203 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2014 | 104 | 0.030 |
Why?
|
| Hong Kong | 3 | 2002 | 91 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 3691 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1443 | 0.030 |
Why?
|
| Cytarabine | 1 | 2019 | 2014 | 0.030 |
Why?
|
| Incidence | 2 | 2019 | 5858 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 2534 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 1407 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2014 | 524 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 2035 | 0.030 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2012 | 109 | 0.020 |
Why?
|
| Hospitalization | 1 | 2021 | 2187 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 4067 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 1397 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 157 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 9052 | 0.020 |
Why?
|
| Animals | 3 | 2022 | 62782 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1998 | 1068 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 167 | 0.020 |
Why?
|
| Chromatin | 1 | 2017 | 1050 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 619 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 1003 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1212 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 2218 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1468 | 0.020 |
Why?
|
| Mitochondria | 1 | 2017 | 1313 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 497 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 594 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3264 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 1137 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1547 | 0.020 |
Why?
|
| Radiotherapy Dosage | 4 | 2000 | 4002 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 6435 | 0.020 |
Why?
|
| Endosonography | 1 | 2012 | 549 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 2501 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4897 | 0.020 |
Why?
|
| Treatment Failure | 3 | 1997 | 1432 | 0.020 |
Why?
|
| Multivariate Analysis | 4 | 1997 | 4346 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 4753 | 0.020 |
Why?
|
| beta Catenin | 1 | 2012 | 693 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 3416 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 3648 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 1994 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 5503 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 743 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 2197 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 6489 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 2 | 2000 | 226 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2017 | 2762 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6783 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 2578 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3362 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 3471 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 6904 | 0.020 |
Why?
|
| Child | 7 | 2003 | 30576 | 0.010 |
Why?
|
| Organizations | 1 | 2003 | 22 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2016 | 7300 | 0.010 |
Why?
|
| Asia | 1 | 2003 | 155 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2017 | 5505 | 0.010 |
Why?
|
| Quality Control | 1 | 2003 | 467 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 255 | 0.010 |
Why?
|
| Paralysis | 1 | 1999 | 54 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 3177 | 0.010 |
Why?
|
| Brachytherapy | 2 | 1997 | 1005 | 0.010 |
Why?
|
| Cranial Nerve Diseases | 1 | 1999 | 77 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 12212 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 2201 | 0.010 |
Why?
|
| Cesium | 1 | 1997 | 19 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 2065 | 0.010 |
Why?
|
| Clavicle | 1 | 1996 | 67 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1995 | 170 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 463 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 2501 | 0.010 |
Why?
|
| Lymph Nodes | 2 | 1996 | 3082 | 0.010 |
Why?
|
| Registries | 1 | 2002 | 2246 | 0.010 |
Why?
|
| Physical Examination | 1 | 1996 | 304 | 0.010 |
Why?
|
| Neck | 1 | 1996 | 392 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1998 | 1732 | 0.010 |
Why?
|
| Probability | 1 | 1994 | 887 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1996 | 1581 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1999 | 1862 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1993 | 751 | 0.010 |
Why?
|
| Remission Induction | 1 | 1998 | 3645 | 0.010 |
Why?
|
| Survival Analysis | 2 | 1993 | 9317 | 0.010 |
Why?
|
| Logistic Models | 1 | 1995 | 3462 | 0.000 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 3981 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2003 | 17070 | 0.000 |
Why?
|